ERBB2 and breast cancer: The gene expression-based molecular subtyping of breast cancers suggested that 88% of the low-ER staining tumors were either categorized as basal-like or HER2-enriched, and only tumors with an ER+ staining intensity of 10% were ideally classified as a luminal subtype of breast cancer [32,33,34].